In preclinical AD, the plasma levels of GFAP were 285.0 [142.6] pg/mL and 185.1 [93.5] pg/mL in the in Aβ positive and Aβ negative cohorts, respectively, in the TRIAD study [159]. This evidence concerns the gene GFAP and Alzheimer disease.